Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus

International Journal of Rheumatic Diseases

Volumn 15, Issue 1, 2012, Pages 62-68

  Islam, Md Nazrul ^a   Hossain, Mohsin ^b   Haq, Syed A ^a   Alam, Mohammad N ^c   Ten Klooster, Peter M ^d   Rasker, Johannes J ^d  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b National Institute of Cardiovascular Diseases   (Bangladesh)

^c Samorita Hospital   (Bangladesh)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Articular; Chloroquine; Cutaneous; Methotrexate; SLE

Indexed keywords

CHLOROQUINE; METHOTREXATE;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MORNING STIFFNESS; NAUSEA; PATIENT GLOBAL ASSESSMENT INDEX; PHYSICIAN GLOBAL ASSESSMENT INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SLE DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ARTHRALGIA; ARTHRITIS; BANGLADESH; BLOOD SEDIMENTATION; CHLOROQUINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857052144     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01665.x     Document Type: Article

References (36)

1. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA (1990) SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long term follow up. Q J Med74, 319-30.
2. Wallace DJ (1994) Antimalarial drugs and lupus. Rheum Dis Clin North Am20, 43-64.
3. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis69, 20-8.
4. Aviña-Zubieta J, Galindo-Rodriguez G, Newman S, et al. (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis57, 582-7.
5. Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM (1999) Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol26, 808-15.
6. Donadio JVS, Glassock RJ (1993) Immunosuppressive drug therapy in lupus nephritis: in depth review. Am J Kidney Dis21(3), 239-50.
7. Kremer JM, Phelps CT (1992) Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90months. Arthritis Rheum35, 138-44.
8. Weinblatt ME, Weissman BN, Holdsworth DE, et al. (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum35, 129-37.
9. Felson DT, Anderson JJ, Meenan RF (1994) The efficacy and toxicity of combination therapy in rheumatoid arthritis. Arthritis Rheum37, 1487-90.
10. Miescher PA, Riethmüller D (1965) Diagnosis and treatment of systemic lupus erythematosus. Semin Hematol2, 1-28.
11. Ferraccioli GF, De Vita S, Bartoli E (1985) Methotrexate benefits in patients with lupus with and without nephritis (Letter). J Rheumatol22, 1442.
12. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB (1988) Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol25, 243.
13. Rothenberg RJ, Graziano FM, Grandote JT, et al. (1988) The use of methotrexate in steroid resistant systemic lupus erythematosus. Arthritis Rheum31, 612-5.
14. Wilke WS, Krall PL, Sheetz RJ, et al. (1991) Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol9, 581-7.
15. Guil Garcia M, Garcia Portales R, Fernandez Nebro A, Belmonte Lopez MA, Camps Garcia MT, de Ramon Garrido E (1993) Effectiveness of the treatment of systemic lupus erythematosus with methotrexate. Med Clin (Barc)101, 361-4.
16. Wilson K, Abeles M (1994) A 2-year, open-ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol21, 1674-7.
17. Arfi S, Numeric P, Grollier L, Panelatti G, Jean-Baptiste G (1995) Treatment of corticodependent systemic lupus erythematosus with low-dose methotrexate. Rev Med Interne16, 885-90.
18. Wise CM, Vuyyuru S, Roberts WN (1996) Methotrexate in nonrenal lupus and undifferentiated connective tissue disease, a review of 36 patients. J Rheumatol23, 1005-10.
19. Kipen Y, Littlejohn GO, Morand EF (1997) Methotrexate use in systemic lupus erythematosus. Lupus6, 385-9.
20. Gansauge S, Breifbart A, Rinaldi N, et al. (1997) Methotrexate in patients with moderate systemic lupus erythematosus. Ann Rheum Dis56(6), 382-5.
21. Sato ET (2001) Methotrexate in systemic lupus erythematosus. Lupus10, 162-4.
22. Sanchez Y, Carvallo A (2004) Methotrexate use in patients with systemic lupus erythematosus. Rev Med Chil132, 195-201.
23. Wong JM, Esdaile JM (2005) Methotrexate in systemic lupus erythematosus. Lupus14, 101-5.
24. Carneiro JRM, Sato EI (1999) Double blind, randomized, placebo controlled clincal trial of methotrexate in systemic lupus erythematosus. J Rheumatol26, 1275-9.
25. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid sparing effects of methotrexate in systemic lupus erythematusous: a double-blind randomized placebo controlled trial. Canadian Network for improved outcomes in systemic lupus. Arthritis Rheum59, 1796-804.
26. Felson DT, Anderson JJ, Boers M, et al. (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum36, 729-40.
27. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum35, 630-40.
28. Ziff M, Esserman P, Mc Ewen C (1956) Observation on the course and treatment of SLE. Arthritis Rheum7, 332-50.
29. Rothfield N (1988) Efficacy of antimalarials in systemic lupus erythematosus. Am J Med85(4A), 53-6.
30. Williams HJ, Egger MJ, Singer JZ, et al. (1994) Comparison of hydroxychloroquine and placebo in the treatment of arthropathy of mild systemic lupus erythematosus. J Rheumatol21, 1437-62.
31. Molad Y, Gorshtein A, Wysenbeek AJ, et al. (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus; prospective long-term study of an Israeli cohort. Lupus11, 356-61.
32. McCarthy CJ, Sheldon S, Ross CW, et al. (1994) Cytogenetic abnormalities and hematologic malignancies associated with the use of alkylating agents in rheumatic disease. Arthritis Rheum37, S428.
33. Rivkees SA, Crawford D (1988) The relationship of gonadal activity and chemotherapyinduced gonadal damage. JAMA259, 2123-5.
34. Siegel M, Reilly EB, Lee SL, et al. (1964) Epidemiology of systemic lupus erythematosus. Time trend and racial differences. Am J Public Health54, 33-43.
35. Wallace DJ (2002) Antimalarial therapies. In: Wallace DJ, Bevra HH (eds). Dubois' Lupus Erythematosus, 6th edn, Chapter 55, pp 1149-72. Lippincott Williams & Willkins, Philadelphia.
36. Canella AC, O'Dell JR (2008) Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine and combination therapies. in: Firestein GS, Budd RC, Harris EDJr, McInnes IB, Ruddy S, Sergent JS (eds) Kelley's Textbook of Rheumatology, 8th edn, Chapter 56, pp 883-908. Elsevier, Philadelphia.